INTRODUCTION {#s1}
============

Colorectal cancer is the third most common malignancy worldwide with approximately 50% patients developing liver metastasis during the course of disease. Hepatic resection represents potentially curative treatment for colorectal liver metastasis (CLM) and offers an opportunity of long-term survival benefit, with 5-yeart overall survival (OS) rate of 37-58% \[[@R1]\]. Although advances in surgical techniques and perioperative care have decreased the morbidity and mortality remarkably in high-volume centers, a considerable proportion of patients have to receive perioperative blood transfusion (PBT) \[[@R2]--[@R4]\]. Transfusion-related immune modulation may compromise the clinical outcomes in oncological surgery. However, data for evaluating the impact of PBT on short- and long-term outcomes following CLM resection are limited due to small sample sizes in most reported studies \[[@R2]--[@R10]\]. In this study, we made a meta-analysis on the presently existing data in the literature to assess this issue.

RESULTS {#s2}
=======

Selection of studies {#s2_1}
--------------------

The initial search yielded 3856 articles, of which 25 published between 1988 and 2017 were finally qualified for the inclusion criteria in the meta-analysis \[[@R2]--[@R9], [@R11]--[@R26]\]. The process of study selection is shown in Figure [1](#F1){ref-type="fig"}. Study characteristics are shown in Table [1](#T1){ref-type="table"}. Two articles from the same institution were included \[[@R5], [@R9]\], the former mainly assessing the impact of transfusion on perioperative morbidity and mortality, and the latter mainly assessing the impact of transfusion on long-term survival. All identified studies were observational design studies involving a total of 10621 patients. Seven studies were from USA \[[@R5], [@R7], [@R9], [@R16], [@R21], [@R22], [@R24]\], four from Italy \[[@R4], [@R8], [@R12], [@R13]\], three from Japan \[[@R3], [@R14], [@R18]\], two from UK \[[@R11], [@R25]\], two from Germany \[[@R20], [@R23]\], one from Sweden \[[@R2]\], one from France \[[@R6]\], one from Spain \[[@R10]\], one from Brazil \[[@R15]\], one from China \[[@R17]\], one from Canada \[[@R19]\], and one from the Netherlands \[[@R26]\]. The blood product transfusion rate was highly variable across studies ranging from 13.5% to 91.5%. The sample size of each study varied from 65 to 1351 patients.

![Flowchart of study selection](oncotarget-08-41740-g001){#F1}

###### Clinical background of studies included in the meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                 Year   No. of\    PT\    M/F       Age,\          TS,cm             No. of\       Morbidity\   Mortality\   5 y-OS\   5 y-DFS\   Study\
                                   patients   (%)              years                            Tumor         (%)          (%)          (%)       (%)        quality
  ------------------------- ------ ---------- ------ --------- -------------- ----------------- ------------- ------------ ------------ --------- ---------- ---------
  Ohlsson \[[@R2]\]         1998   111        91.5   60/51     ≥ 65, n=75     ≥ 5, n=54         ≥ 2, n=50     17.1         3.6          25        19         6

  Ambiru \[[@R3]\]          1999   168        77.4   104/64    62 (21-80)     ≥ 5, n=56         ≥ 4, n = 38   29.7         3.5          26        NA         6

  Ercolani \[[@R4]\]        2002   245        43.0   144/102   \> 60, n=115   NA                ≥ 3, n=41     18.7         0.8          34        NA         7

  Kooby \[[@R5]\]           2003   1351       54     772/579   NA             NA                NA            40           3.7          36        NA         8

  Laurent \[[@R6]\]         2003   311        15.7   209/102   63 (31--86)    ≥5, n=142         \> 3, n=42    29.9         2.8          36        24         9

  Zakaria \[[@R7]\]         2007   662        55.2   404/258   60 ± 11        NA                NA            NA           2.8          42        NA         7

  Arru \[[@R8]\]            2008   297        53.2   171/126   ≥ 65, n=120    \> 5, n=98        ≥ 2, n=117    17.0         NA           27.5      NA         9

  Ito \[[@R9]\]             2008   1067       44.6   596/471   61 ± 0.37      5.0 ± 3.7         3.4 ± 0.05    42.2         Excluded     41        25         7

  Hernández \[[@R10]\]      2009   210        24.2   140/70    61 ± 12        ≥ 5, n=80         ≥ 3, n=67     42.9         1.4          53.8      23         7

  Farid \[[@R13]\]          2010   705        21.1   442/263   46 (23--91)    4 (0.1--23)       3 (1--21)     7.9          3.5          34        22         8

  Giuliante \[[@R14]\]      2010   543        23     309/234   62 (24--83)    4.5 ± 3.0         2.0 (1--14)   18.5         1.3          36.5      25.7       7

  Gruttadauria \[[@R15]\]   2011   127        40.2   72/55     63 (55--69)    NA                NA            47.2         NA           NA        NA         8

  Kaibori \[[@R16]\]        2012   119        37.8   70/49     \>64, n=62     \>3.5, n=59       ≥3, n=38      22.6         0            38.7      33.7       8

  Ribeiro \[[@R17]\]        2012   170        31.7   91/79     59 (23-80)     \> 5, n=72        ≥ 3, n=64                  2.9          64.9      39.1       7

  Cannon \[[@R18]\]         2013   239        26.8   NA        61.4           4.6               \-            47.3         2.5          32.7      18.1       8

  Jiang \[[@R19]\]          2013   139        25.8   91/48     58 (25--82)    2.5(0.3--11.5)    ≥ 2, n=66     12           0            53        48         9

  Shiba \[[@R20]\]          2013   65         41.5   45/20     64.1±10.0      NA                1.8 ±2.1      29.2         NA           46.7      NA         7

  Hallet \[[@R21]\]         2015   483        27.5   299/184   NA             NA                NA            NA           4.8          56.8      27.0       9

  Schiergens \[[@R22]\]     2015   292        36.3   193/99    65 (21-86)     \> 5, n=52        ≥ 3, n=43     40           5            49        49         9

  Postlewait \[[@R23]\]     2016   456        30.7   252/204   58.6 ± 12.0    4.6 ± 3.2         1.9 ± 1.2     21.2         1.3          36.5      NA         7

  Zimmitti \[[@R24]\]       2016   510        17.6   309/201   57 (23--87)    2.3 (0.3--11.5)   1 (0--80)     40.4         Excluded     56.6      31.6       7

  Kulik \[[@R25]\]          2016   983        52.2   605/378   ≥ 70, n=235    \> 5, n=377       ≥ 2, n=501    17.7         1.2          NA        NA         6

  Margonis \[[@R26]\]       2016   433        13.5   255/178   54 (44--64)    2.8 (1.7--4.5)    5 (2--7)      NA           NA           49.3      NA         6

  Bell \[[@R27]\]           2017   727        13.5   466/261   64 (25--88)    \> 5, n=270       \> 3, n=281   26           4.5          NA        NA         6

  Olthof \[[@R28]\]         2017   208        NA     136/72    64 (56--71)    3.1 (2--5.1)      2 (1--3)      36           1            59        29         8
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: PT= perioperative transfusion, M= male, F=female, TS=tumor size, NA=not available; OS=overall survival; DFS=disease-free survival

Meta-analysis {#s2_2}
-------------

Table [2](#T2){ref-type="table"} shows the results for the outcomes.

###### Meta-analysis of short and long-term outcomes

  Outcome of interest           Studies   Participants   OR/WMD   95% CI            *P*-value   *I*^2^ (%)
  ----------------------------- --------- -------------- -------- ----------------- ----------- ------------
  Clinicopathologic features                                                                    
  Male gender                   3         1231           0.58     0.46, 0.75        \<0.001     0
  Age                           4         1470           0.10     -1.28, 1.47       0.10        40
  Body mass index               2         695            -0.26    -1.26, 0.74       0.62        0
  Preoperative anemiaa          2         775            2.51     1.83, 3.45        \<0.001     0
  ASA \> 2                      2         748            1.15     0.59, 2.24        0.69        76
  Extended or major resection   4         1470           1.64     1.28, 2.09        \<0.001     0
  Duration of surgery (min)     2         775            55.64    42.14, 69.14      \<0.001     0
  Blood loss (mL)               4         1470           726.88   376,91, 1076.84   \<0.001     93
  Tumor size (cm)               2         695            0.95     -0.13, 2.03       0.09        78
  Tumor number                  2         695            -0.03    -0.49, 0.44       0.90        59
  Negative surgical margin      4         1470           1.03     0.70, 1.51        0.89        0
  Postoperative outcomes                                                                        
  Overall morbidity             6         2833           1.98     1.49, 2.33        \<0.001     51
  Major complication            4         2226           2.12     1.26, 3.58        0.005       76
  Mortality                     5         2821           4.13     1.96, 8.72        \<0.001     51
  Length of stay (day)          3         2099           4.42     1.15, 7.69        0.008       82
  Long-term outcomes                                                                            
  Overall survival              21        8732           1.24     1.11, 1.38        0.0002      71
  Disease-free survival         11        5018           1.38     1.23, 1.56        \<0.001     17

Abbreviations: OR=odds ratio, WMD=weighted mean difference, CI= confidence interval,

ASA= American Society of Anesthesiologists

Four studies compared the characteristics of transfused patients versus those nontransfused patients \[[@R16], [@R19]--[@R21]\]. Pooled analysis showed that transfusion was associated with female gender (*P* \<0.001), higher prevalent preoperative anemia (*P* \<0.001), more extended or major hepatectomy (*P* \<0.001), increased estimated blood loss (*P* \<0.001), and longer duration of surgery (*P* \<0.001).

The impact of PBT on perioperative outcomes was evaluated in 6 studies \[[@R5], [@R11], [@R13], [@R14], [@R16], [@R20]\]. As shown in Figure [2](#F2){ref-type="fig"}, compared with nontransfused patients, transfused patients experienced higher overall morbidity (*P* \<0.001), more major complication (Clavien-Dindo class 3--5 \[[@R27]\]) (*P* =0.005), higher mortality (*P* \<0.001), and longer lengths of hospital stay (*P* \<0.001).

![Results of the meta-analysis on perioperative outcomes\
**a**. overall morbidity; **b**. major complications; **c**. mortality; and **d**. lengths of hospital stay.](oncotarget-08-41740-g002){#F2}

The impact of PBT on OS and disease-free survival (DFS) was evaluated in 21 \[[@R2]--[@R9], [@R11], [@R12], [@R15]--[@R19], [@R21]--[@R26]\] and 11 \[[@R6], [@R8], [@R11], [@R12], [@R15]--[@R17], [@R19], [@R20], [@R22]\] studies, respectively. The 5-year OS and DFS of transfused patients ranged from 21.5% to 62.7% and 14.7% to 42% respectively *vs*. 24--66.2% and 19.5--55% in nontransfused patients. Pooled analysis showed that transfusion correlated with poor OS (*P* =0.0002) (Figure [3](#F3){ref-type="fig"}) and DFS (*P* \<0.001) (Figure [4](#F4){ref-type="fig"}). The summary of risk ratio (RR) estimates by multivariate analysis was 1.37 (95% confidence intervals \[CI\] =1.12--1.68; *P* =0.002) in 11 studies \[[@R2], [@R6]--[@R8], [@R12], [@R17]--[@R19], [@R24]--[@R26]\] for OS, and 1.40 (95% CI =1.25--1.58; *P* \<0.001) for DFS in six studies \[[@R6], [@R8], [@R11], [@R17], [@R19], [@R20]\]. In sensitivity analysis, removing of any single study from the analysis did not affect the overall results regarding the negative association between transfusion and long-term survival (data not shown).

![Results of the meta-analysis on overall survival](oncotarget-08-41740-g003){#F3}

![Results of the meta-analysis on disease-free survival](oncotarget-08-41740-g004){#F4}

There was significant heterogeneity between studies (I^2^ =71%) regarding the impact of PBT on OS. In meta-regression analysis, year of publication, sample size, and country of patients were significant sources of heterogeneity (Table [3](#T3){ref-type="table"}).

###### Meta-regression analysis between pooled relative risk and co-variates of overall survival

  Co-variates           Coefficient   95% CI           Std. Err.   *P*-value
  --------------------- ------------- ---------------- ----------- -----------
  Year of publication   0.2546        0.1310, 0.3783   0.0631      \<0.001
  Sample size           0.1655        0.0296, 0.3015   0.0694      0.017
  Country of patients   0.1160        0.0953, 0.1367   0.0106      \<0.001

Abbreviations: CI =confidence interval

Publication bias {#s2_3}
----------------

A funnel plot reveals asymmetry for the effect of PBT on OS indicating the presence of publication bias (Figure [5](#F5){ref-type="fig"}).

![Funnel plot for the results from overall survival](oncotarget-08-41740-g005){#F5}

DISCUSSION {#s3}
==========

While blood transfusion is important in maintaining hemodynamic stability and end organ perfusion during complex surgeries, it still carries significant risks, including incompatibility, transmission of infectious agents, coagulopathy, allergic reactions, and tumor-promoting action \[[@R30]\]. Since Burrows and Tartter first reported that PBT may worsen the postoperative survival of patients with bowel cancer in 1982 \[[@R31]\], a large number of authors have investigated the impact of PBT on clinical outcomes in patients with cancer subjected to surgery. In the field of hepatopancreaticobiliary oncological surgery, a meta-analysis of 23 studies reported that patients receiving PBT had significantly lower 5-year survival after curative-intent pancreatic surgery (OR, 2.43, 95% CI =1.90--3.10) \[[@R32]\]. Another meta-analysis of 22 studies noted that hepatocellular carcinoma patients receiving PBT had an increased risk of all-cause death at 3 and 5 years after surgery (respectively: OR = 1.92, 95% CI, 1.61-2.29; OR = 1.60, 95% CI, 1.47-1.73) compared with those without PBT \[[@R33]\]. In contrast, the evidence is less clear in CLM surgery. To the best of our knowledge, this is the first meta-analysis that selectively focused on surgical CLM populations. The result clearly indicates that PBT compromised long-term survival dramatically.

Beyond its deleterious effect on long-term outcomes after surgery, PBT is also associated with adverse perioperative sequelae as measured by overall morbidity, major complications, mortality, and length of stay in the current study. More specifically, more occurrences of postoperative infection or liver failure were observed in patients receiving PBT \[[@R6], [@R11]\]. In a recent review of 712 consecutive elective hepatectomy (all diseases), Hallet et al. \[[@R34]\] found that PBT was associated with an increased rate of major complications and a longer length of hospital stay. The observations from non-hepatic surgery also demonstrated similar results \[[@R35], [@R36]\].

An important issue is whether the association between PBT and the outcome variables analyzed represents a causative effect or whether there are unmanageable confounders acting inwardly. It can be presumed certain that the transfused patients may represent a compromised and vulnerable cohort, and poor outcomes may be attributed to other factors associated with PBT unless otherwise further confirmed by a multivariate model \[[@R20]\]. Indeed, the results of our pooled data of multivariate RR are similar to the findings from overall analysis regarding long-term survival. Although we were unable to pool multivariate RR for perioperative outcomes due to insufficient data, in one included study, PBT was identified at multivariate analysis as a significant predictor of overall morbidity, major complications and mortality after other variables were adjusted \[[@R5]\]. Therefore, there are risks linked to poor postoperative outcomes inherently associated with transfusion *per se* rather than a confounder.

The mechanism underlying the detrimental effect of PBT on postoperative outcomes after oncologic surgery remains to be elucidated. One possible reason is the immunosuppressive effect of transfusion. The observed alterations include suppression of cytotoxic cells and monocyte activity, release of immunosuppressive prostaglandins, inhibition of interleukin-2 production, and increase in suppressor T-cell activity \[[@R30]\].

This meta-analysis has several potential limitations. First, all included studies are observational studies that provided a low level of evidence. Studies may have differed with regard to the baseline characteristics of the patients, tumor size or disease stage, operative procedures, the amount of blood loss, adjuvant treatment, and the follow-up duration. The results therefore are susceptible to heterogeneity. Second, the timing or amount of transfusion received was not taken into account because most of these published studies lacked relevant information. Finally, the review was restricted to articles published in English. This selection could favor the positive studies, as positive results tend to be published in English-language journals, while negative studies tend to be reported in native languages. There is therefore a publication bias.

In conclusion, PBT has a detrimental impact on clinical outcomes in patients undergoing CLM resection. Both surgeons and anesthesiologists need to manage perioperative care from various aspects to minimize the use of transfusion.

MATERIALS AND METHODS {#s4}
=====================

This study was done in accordance with the recommendations of the preferred reporting items for systematic reviews and meta-analyses (PRISMA) \[[@R28]\].

Study selection and criteria for inclusion {#s4_1}
------------------------------------------

A systematic search of PubMed, Science Citation Index, and Embase databases was performed to identify relevant articles from the time of inception to March 2017 using the following key words: colorectal liver metastases, liver resection, and transfusion. Manual search of reference lists of all retrieved articles was carried out to identify additional studies.

Original publications in the English language examining the impact of PBT on the on short- and long-term outcomes following CLM resection were eligible. Letters, reviews, abstracts, editorials, expert opinions, non-English language papers, duplicated studies, and animal studies were excluded.

Data extraction and outcomes of interest {#s4_2}
----------------------------------------

Two reviewers (XL and YL, respectively) independently extracted relevant data regarding the characteristics of study and outcomes of interest from each selected article by using standardized data extraction forms. Discrepancies were resolved through discussion and consensus.

The outcomes of interest were clinicopathologic characteristics, postoperative morbidity and mortality, OS and DFS.

Assessment of methodological quality {#s4_3}
------------------------------------

The methodological quality of included studies was assessed by using the Newcastle-Ottawa Scale. Scores are assigned for patient selection, comparability of the study groups, and outcome assessment \[[@R29]\].

Statistical analysis {#s4_4}
--------------------

The effect measures estimated were odds ratios (OR) 95% CI for dichotomous variables and weighted mean difference (WMD) with a 95% CI for continuous data. The RR with 95% CI was used to assess the prognostic value of transfusion. The I^2^ statistic was calculated to assess the heterogeneity in results across studies with values\>50% representing substantial heterogeneity. A funnel plot based on the OS was used to detect the possibility of publication bias. Sensitivity analyses were carried out to investigate the impact of individual study on the overall outcome of the meta-analysis. Meta-regression was performed with the following co-variates: sample size, year of publication, and country of patients. Statistical analyses were performed with Review Manager version 5.3 (The Cochrane Collaboration, Software Update, Oxford) and Stata™ version 8.0 (Stata Corporation, College Station, Texas, USA). Values of *P* \< 0.05 were considered statistically significant.
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